Online citations, reference lists, and bibliographies.

Role Of MRP-1 And GST-Pi In MDR And Their Inhibition By Indomethacin In AML

Samia A. Ebeed, N. Sadek, Ebtsam R. Zaher, M. M. Mahmoud, Gihan Nabil, Sanaa A. El-Benhawy
Published 2017 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Abstract Background MDR continues to be a major challenge to effective chemotherapeutic interventions against cancer. Defining major factor contributing to MDR and inhibiting their action may thus be used for reversing MDR. Aim This work aimed to evaluate the role played by MRP-1 and GST-Pi in MDR, and to explore the possible role of indomethacin as an inhibitor of chemotherapy resistance in patients with AML. Subjects and methods The study included 2 groups, one included 20 healthy volunteers and the second included 50 AML patients. All patients received one cycle of standard induction chemotherapy, then regrouped according to their response to either CR group or unremitted group. Unremitted patients received a second cycle of chemotherapy combined with indomethacin. From each subject a blood sample was drawn before and after the 1st cycle of chemotherapy and after the 2nd cycle. From blood, mononuclear cells were separated, mRNA was extracted, and RT-PCR was carried out to detect GST-Pi and MRP-1 gene expression. Results GST-Pi expression in CR group was 60% before therapy that significantly decreased to 30% after therapy. While in unremitted group, its expression significantly increased from 30% before to 80% after therapy. GST-Pi positive patients had a significantly lower overall and disease free survival time than GST-Pi negative patients (P = 0.000 and 0.039, respectively). While MRP-1 expression was so low (20%) and remained unchanged after therapy in both groups. MRP-1 expression did not affect overall or disease free survival. Taking indomethacin with 2nd cycle of chemotherapy in unremitted patients resulted in a significant inhibition of GST-Pi expression and a significantly longer overall survival time than those taking 2nd cycle chemotherapy alone (P = 0.034). Conclusion MRP-1 is not likely to contribute to MDR, while GST-Pi might have a role in MDR phenotype in AML patients. Furthermore, GST-Pi inhibition significantly reduced MDR in AML patients.
This paper references
10.2174/1568011043482160
Structure of multidrug-resistance proteins of the ATP-binding cassette (ABC) superfamily.
G. Altenberg (2004)
10.2967/jnumed.107.050153
Multidrug Resistance in Acute Myeloid Leukemia: Potential New Therapeutics
J. Weisburg (2008)
10.1186/1756-9966-33-37
The multiple facets of drug resistance: one history, different approaches
E. L. Niero (2014)
10.1146/annurev-pharmtox-011613-135959
Targeting multidrug resistance protein 1 (MRP1, ABCC1): past, present, and future.
S. Cole (2014)
10.1080/1120009X.1989.11738926
Effects of synthetic retinoids on the growth of bacteria and their susceptibility to antibiotics.
A. Flemetakis (1989)
[Expressions of LRP, GST-pi and MRP1 in acute leukemia patients and its clinical significance].
Bin-Tao Huang (2007)
SHG AML96 Study Group: MDR1 and MRP1 gene expression are independent predictors for treatment outcome in adult acute myeloid leukaemia
M Schaich (2005)
10.1038/sj.leu.2401634
Drug resistance factors in acute myeloid leukemia: a comparative analysis
M. Filipits (2000)
10.1038/sj.bjc.6602958
Prognostic impact of multidrug resistance gene expression on the management of breast cancer in the context of adjuvant therapy based on a series of 171 patients
L. Moureau-Zabotto (2006)
10.1038/sj.bjc.6604010
Indomethacin induces apoptosis via a MRP1-dependent mechanism in doxorubicin-resistant small-cell lung cancer cells overexpressing MRP1
D. J. de Groot (2007)
10.1111/j.1365-2141.2004.05319.x
MDR1 and MRP1 gene expression are independent predictors for treatment outcome in adult acute myeloid leukaemia
M. Schaich (2005)
10.1007/978-1-59745-035-5_12
Glutathione and Glutathione S -Transferases in Drug Resistance
V. Findlay (2006)
10.3892/IJO.32.4.931
Alleviation of the drug-resistant phenotype in idarubicin and cytosine arabinoside double-resistant acute myeloid leukemia cells by indomethacin.
J. H. Song (2008)
10.3390/molecules18066584
Indomethacin Inhibits Cancer Cell Migration via Attenuation of Cellular Calcium Mobilization
Yuh-Cherng Guo (2013)
10.1038/sj.leu.2402236
Activity and expression of the multidrug resistance proteins P-glycoprotein, MRP1, MRP2, MRP3 and MRP5 in de novo and relapsed acute myeloid leukemia
D. V. D. Kolk (2001)
10.1007/s00280-014-2566-x
Cytoprotective and regulatory functions of glutathione S-transferases in cancer cell proliferation and cell death
S. Singh (2014)
10.1200/JCO.1993.11.1.49
A pilot study of pi-class glutathione S-transferase expression in breast cancer: correlation with estrogen receptor expression and prognosis in node-negative breast cancer.
L. Gilbert (1993)
10.1590/S1516-31802008000300007
Expression of MRP1 gene in acute leukemia.
F. Mahjoubi (2008)
10.1016/j.bbagen.2012.11.019
Glutathione transferases, regulators of cellular metabolism and physiology.
P. Board (2013)
10.1038/bjc.1997.145
Indomethacin-mediated reversal of multidrug resistance and drug efflux in human and murine cell lines overexpressing MRP, but not P-glycoprotein.
M. Draper (1997)
10.1517/17425255.2014.972933
Natural compounds to overcome cancer chemoresistance: toxicological and clinical issues
E. Turrini (2014)
Multidrug resistance-associated protein in acute myeloid leukemia: No impact on treatment outcome.
M. Filipits (1997)
10.1080/07357900701788072
Expression of Multidrug Resistance-Related Proteins p-Glycoproteinglutathione-s-Transferases, Topoisomerase-II and Lung Resistance Protein in Primary Gastric Cardiac Adenocarcinoma
Hongcan Shi (2008)
10.1007/s00280-005-0162-9
Indomethacin overcomes doxorubicin resistance with inhibiting multi-drug resistance protein 1 (MRP1)
Seita Matsunaga (2005)
10.1179/joc.2003.15.4.374
The Clinical Relevance of the Expression of Several Multidrug-Resistant-Related Genes in Patients with Primary Acute Myeloid Leukemia
S. Galimberti (2003)
10.1007/978-1-60761-416-6_4
Mechanisms of multidrug resistance in cancer.
J. Gillet (2010)
10.1016/0006-291X(84)90878-7
Inhibition of purified glutathione S-transferases by indomethacin.
F. Nicholls (1984)
10.1111/j.1600-0609.1997.tb00979.x
Five putative drug resistance parameters (MDR1/P‐glycoprotein, MDR‐associated protein, glutathione‐S‐transferase, bcl‐2 and topoisomerase IIα) in 57 newly diagnosed acute myeloid leukaemias
A. Lohri (1997)
10.1021/bi300559m
New insights into the mechanism of JNK1 inhibition by glutathione transferase P1-1.
A. De Luca (2012)
The pharmacology of cancer resistance.
R. O'Connor (2007)
Expression of multidrug resistance-related proteins p-glycoprotein, glutathione-s-transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma.
Hongcan Shi (2008)
10.3343/KJLM.2007.27.4.229
[Treatment outcome of multidrug resistance related mRNA expression and c-jun-N-terminal kinase activity in patients with acute myeloid leukemia].
J. H. Do (2007)



Semantic Scholar Logo Some data provided by SemanticScholar